GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.
The studies behind this compound did not test timing or food state as variables, so we are not going to invent a rule. Pick a time you can keep to consistently.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Weeks 1–2 | 1.4 mg | daily | 0.06 mL | 6 u | 14 | 19.6 mg |
| Weeks 3–4 | 2.8 mg | daily | 0.12 mL | 12 u | 14 | 39.2 mg |
| Week 5 onward per 4 weeks from here on |
4.2 mg | daily | 0.18 mL | 18 u | 28 | 117.6 mg |
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial |
|---|---|---|---|---|---|
| Low reported | 1.4 mg | 1× daily (≈1 mg GHK-Cu) | 0.06 mL | 6 u | 50 doses |
| Standard | 2.8 mg | 1× daily (≈2 mg GHK-Cu) | 0.12 mL | 12 u | 25 doses |
| Upper reported | 4.2 mg | 1× daily (≈3 mg GHK-Cu) | 0.18 mL | 18 u | 16 doses |
A fixed-ratio combination vial. Because the components are pooled at a fixed ratio, you cannot titrate one without moving the others — the practical consequence is that dosing is driven by whichever component has the narrowest window. A 70 mg vial is roughly 71% GHK-Cu by mass.
Buy GLOW BlendPaid affiliate links.
Adding 3 mL of bacteriostatic water to a 70 mg vial gives 23.3 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.
Published and reported figures for GLOW Blend run from 1.4 mg to 4.2 mg, typically 1× daily (≈1 mg GHK-Cu).4 mg to 4.2 mg, typically 1× daily (≈1 mg GHK-Cu). This site lists each figure with the source it came from rather than giving a single recommended number.
At 23.3 mg/mL, a 1.4 mg dose is 6 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 50 doses.
GLOW Blend is graded preclinical. Laboratory and animal data only. No human dosing trials have been published. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.
GLOW pairs a skin-and-collagen compound with two repair compounds. GHK-Cu is the bulk of the vial and carries the cosmetic and dermal side — it is the most studied copper peptide for collagen and skin quality. BPC-157 and TB-500 are the tissue-repair pair, included at a tenth of the GHK-Cu amount each.
The logic is coverage rather than synergy: three different mechanisms in one injection instead of three separate vials and three separate draws. There is no published trial of the combination, so the case for combining them rests on the individual compounds, not on evidence that they work better together.
Need this on one page to print, screenshot or send?
Make a dose card →Side-by-side with the compounds it is most often weighed against — doses, evidence tier and how each is mixed.
Compounds in the same class, or browse the full catalogue.
An equal-parts repair and anti-inflammatory pairing — 10 mg of each in a 20 mg vial, so every dose splits evenly down the middle a…
A GHRH analogue paired with a selective ghrelin receptor agonist — the pairing rationale is that the two receptors act synergistic…
Every compound compared in one table: dose range, how often, half-life and evidence tier.